Risk factors for cardiovascular disease in patients with non-alcoholic fatty liver disease with polymorbidity

QR Code

Risk factors for cardiovascular disease in patients with non-alcoholic fatty liver disease with polymorbidity

Aim. To study the associations of the frequency and values of parameters of the main risk factors (RF) of cardiovascular diseases (CVD) and the degree of transnosological polymorbidity (PM) in patients with nonalcoholic fatty liver disease (NAFLD).Material and methods. The analysis of 3667 medical r...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. V. Sevostyanova, Yu. A. Nikolaev, I. M. Mitrofanov, V. Ya. Polyakov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2019-11-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	nonalcoholic fatty liver disease risk factors cardiovascular diseases polymorbidity gender differences
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1220
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
by: Zhiqing Zhang, et al.
Published: (2025-06-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

PSpa Treatment of Nonalcoholic Fatty Liver Disease in Patients with Metabolic Syndrome with Drinking Mineral Water of Essentuki Type Applications
by: T. E. Fedorova, et al.
Published: (2012-12-01)

Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy
by: A. V. Nelidova, et al.
Published: (2022-01-01)

Is nonalcoholic fatty liver disease associated with metabolic syndrome? An experience from a medical college of West Bengal, India
by: Sounak Sinha, et al.
Published: (2025-06-01)

Features of gender, age, social factors and polymorbidity in patients, undergone COVID-19
by: Yu. A. Nikolaev, et al.
Published: (2024-08-01)

Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease
by: K. A. Andreev, et al.
Published: (2022-01-01)

EXPRESSION OF TLR2, TLR3, TLR4 AND PROINFLAMMATORY TNF AND IL-6 CYTOKINES IN LIVER BIOPSIES OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS
by: A. V. Bogolyubova, et al.
Published: (2019-12-01)

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk
by: O. M. Drapkina, et al.
Published: (2016-09-01)

Ultrasound Score of Liver Steatosis Severity in the Diagnosis of Peripheral Arterial Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
by: A. S. Kuznetsova, et al.
Published: (2023-06-01)

Role of oxidative stress and glutathione system in the pathogenesis of nonalcoholic fatty liver disease
by: T. E. Promenasheva, et al.
Published: (2014-09-01)

Analysis of prevalence of risk factor of nonalcoholic fatty liver disease in the Buryat Republic
by: E. G. Naydanova
Published: (2015-04-01)

Adherence and barriers to Mediterranean diet in Tunisian patients with nonalcoholic fatty liver disease
by: Ayadi Shema, et al.
Published: (2024-12-01)

Drug-Induced Fatty Liver Disease
by: A. P. Pereverzev, et al.
Published: (2020-06-01)

Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease
by: Yu Hong, et al.
Published: (2025-07-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Chi-Kuei Hsu, et al.
Published: (2025-07-01)

Non-pharmacological methods of treatment and rehabilitation of patients with non-alcoholic fatty liver disease
by: V. A. Akhmedov, et al.
Published: (2021-06-01)

Interrelation of blood lipid spectrum, level of systemic inflammation and mass of body in patients with coronary heart disease in combination with nonalcoholic fatty liver disease and their dynamics in terms of secondary prevention.
by: O. V. Kuryata, et al.
Published: (2014-11-01)

Global Trends in Non-Invasive Techniques for the Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease: A Bibliometric and Visualization Analysis
by: Cai JW, et al.
Published: (2025-07-01)

Creatinine-to-cystatin C ratio and all-cause and cardiovascular mortality in U.S. adults with nonalcoholic fatty liver disease: a nationwide cohort study
by: Yuanyuan Chen, et al.
Published: (2025-06-01)

Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
by: Minkwan Kim, et al.
Published: (2025-07-01)

Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
by: V. T. Ivashkin, et al.
Published: (2025-03-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

Correction: Creatinine-to-cystatin C ratio and all-cause and cardiovascular mortality in U.S. adults with nonalcoholic fatty liver disease: a nationwide cohort study
by: Yuanyuan Chen, et al.
Published: (2025-06-01)

Risk factors in patients with non-alcoholic fatty liver disease associated with arterial hypertension, overweight and obesity
by: Yu. A. Nikolaev, et al.
Published: (2020-12-01)

Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies)
by: O. M. Drapkina, et al.
Published: (2025-03-01)

Polymorbidity and indicators of carbohydrate, lipid and purine metabolism in patients with arterial hypertension
by: Yu. A. Nikolaev, et al.
Published: (2021-08-01)

LIVER DAMAGE IN PSORIASIS AND PSORIATIC ARTHRITIS: A LITERATURE REVIEW
by: Yu. L. Korsakova, et al.
Published: (2017-09-01)

The clinical signiﬁcance of adiponectimics in formation of aﬀected target-organs during the metabolic syndrome associated with nonalcoholic fatty liver disease
by: E. A. Saginova, et al.
Published: (2011-03-01)

Disrupted host-microbiota crosstalk promotes nonalcoholic fatty liver disease progression by impaired mitophagy
by: Wenjing Yin, et al.
Published: (2025-07-01)

The effect of non-alcoholic fatty liver disease on the development of cardiovascular diseases
by: N. A. Starodubtseva, et al.
Published: (2025-03-01)

POLYMORBIDITY: SPECIFICS OF CO-DEVELOPMENT AND CONCOMITANCE OF SEVERAL DISEASES IN ONE PATIENT
by: R. G. Oganov, et al.
Published: (2016-08-01)

Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)
by: Alexander A. Baranov, et al.
Published: (2025-05-01)

C-reactive protein as an indicator of polymorbidity in patients with arterial hypertension
by: E. V. Sevostyanova, et al.
Published: (2022-04-01)

Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
by: G. Yu. Knorring, et al.
Published: (2024-08-01)

Hepatic fibrosis as an additional risk factor for the development of cardiovascular disorders in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease
by: O.M. Bilovol, et al.
Published: (2021-06-01)

NON-ALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK: SCIENTIFIC PROBLEM STATE
by: O. M. Drapkina, et al.
Published: (2017-11-01)